Kazuaki Harada

Sapporo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Journal: Future oncology (London, England)

Published: April 15, 2026

A multicenter retrospective study on the clinical features of patients with human epidermal growth factor receptor 2-positive colorectal cancer (HGCSG2304).

A multicenter retrospective study on the clinical features of patients with human epidermal growth factor receptor 2-positive colorectal cancer (HGCSG2304).

Journal: International journal of clinical oncology

Published: March 26, 2026

High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes.

High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes.

Journal: Cancers

Published: February 24, 2026

Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).

Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).

Journal: Japanese journal of clinical oncology

Published: January 06, 2026

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: December 22, 2025

Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer.

Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer.

Journal: BMC cancer

Published: October 28, 2025

Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.

Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.

Journal: Journal of pharmaceutical health care and sciences

Published: September 04, 2025

Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series.

Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series.

Journal: Frontiers in oncology

Published: August 15, 2025

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: June 30, 2025

Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.

Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.

Journal: International journal of molecular sciences

Published: June 06, 2025

Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).

Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: March 17, 2025

Subcutaneous adipose tissue radiodensity as a predictor of poor prognosis in advanced biliary tract cancer.

Subcutaneous adipose tissue radiodensity as a predictor of poor prognosis in advanced biliary tract cancer.

Journal: Journal of hepato-biliary-pancreatic sciences

Published: January 08, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026